International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-4 : 704-713 doi: 10.5281/zenodo.16889840
Original Article
Compare The Epidemiological And Social Factors Between Acceptors And Non-Acceptors Of Post Partum Intrauterine Contraceptive Device Insertion As A Contraceptive Device
 ,
 ,
Published
Aug. 17, 2025
Abstract

INTRODUCTION:  According to the 2021 census, India has 140.76 crore people, making it the most populous country in the world. It adds over 25 million births annually, making up 17.76% of the world's population. Family planning is most effective during the postpartum period. Research indicates that giving birth fewer than two years apart can increase maternal mortality and obstetric problems. Therefore, using contraception is required. This study aids in identifying the demographic and socioeconomic variables related to post-placental and post-cesarean Copper-T implantation. Determining the elements linked to PPIUCD acceptability and non-acceptability is also beneficial.

METHODOLOGY : In order to determine eligibility, their labor event data were examined, and the woman was questioned regarding her acceptance or rejection of PPIUCD (Cu-T). In the postpartum and postoperative wards, women who qualified for PPIUCD were located and contacted. The parturient provided written informed consent to participate in the study. The researcher filled out questionnaires. The following variables were gathered through the use of a structured questionnaire: the women's social demographics, obstetric and gynecological characteristics, prior contraceptive methods, information source and awareness of the PPIUCD, reasons for accepting or declining PPIUD insertion, and their desires for future pregnancies.

RESULTS:   Male condoms were the most widely utilized form of birth control among parturients (17.12%). Among the least popular techniques was interval IUCD (2.7%). Acceptance of PPIUCD was statistically substantially correlated with both previous interval IUCD users and parturients who had never used contraception (p ˂ 0.05). A small percentage of women (5.86%) report extremely painful PPIUCD insertions, whereas around half (50.90%) report no discomfort at all. Over half (51.35%) of the women who accepted PPIUCD did so because of its long-term effects.

CONCLUSION:  According to the study, the PPIUCD is especially safe and has low side effects. Even at the prenatal clinic, patients should be informed of the benefits of family planning, which can prevent 20–35% of maternal deaths and over 20% of newborn deaths.

Recommended Articles
Loading Image...
Volume-6, Issue-4
Citations
1510 Views
68 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved